Search

Your search keyword '"Poorbaugh, Josh"' showing total 17 results
Start Over Author "Poorbaugh, Josh"
17 results on '"Poorbaugh, Josh"'

3. Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL‐17A (LY3509754): A Phase I Randomized Placebo‐Controlled Study

Author

Datta‐Mannan, Amita, primary, Regev, Arie, additional, Coutant, David E., additional, Dropsey, Andrew J., additional, Foster, Joanne, additional, Jones, Spencer, additional, Poorbaugh, Josh, additional, Schmitz, Carsten, additional, Wang, Evan, additional, and Woodman, Michael E., additional

Published
2024
Full Text
View/download PDF

4. Evaluation of plasma IL-21 as a potential biomarker for type 1 diabetes progression

Author

Schroderus, Anna-Mari, primary, Poorbaugh, Josh, additional, McElyea, Samantha, additional, Beasley, Stephanie, additional, Zhang, Lin, additional, Näntö-Salonen, Kirsti, additional, Rintamäki, Reeta, additional, Pihlajamäki, Jussi, additional, Knip, Mikael, additional, Veijola, Riitta, additional, Toppari, Jorma, additional, Ilonen, Jorma, additional, Benschop, Robert J., additional, and Kinnunen, Tuure, additional

Published
2023
Full Text
View/download PDF

5. COVID-19 symptom relationship to antibody response and ACE2 neutralization in recovered health systems employees before and after mRNA BNT162b2 COVID-19 vaccine

Author

Huhn, Gregory, primary, Poorbaugh, Josh, additional, Zhang, Lin, additional, Beasley, Stephanie, additional, Nirula, Ajay, additional, Brothers, Jennifer, additional, Welbel, Sharon, additional, Wilson, James, additional, Gillani, Sheena, additional, Weber, Kathleen M., additional, Morack, Ralph, additional, Keckler, Kody, additional, and Benschop, Robert J., additional

Published
2022
Full Text
View/download PDF

6. The anti–SARS-CoV-2 monoclonal antibody bamlanivimab minimally affects the endogenous immune response to COVID-19 vaccination

Author

Benschop, Robert J., primary, Tuttle, Jay L., additional, Zhang, Lin, additional, Poorbaugh, Josh, additional, Kallewaard, Nicole L., additional, Vaillancourt, Peter, additional, Crisp, Melissa, additional, Trinh, Thi Ngoc Vy, additional, Freitas, Joshua J., additional, Beasley, Stephanie, additional, Daniels, Montanea, additional, Haustrup, Natalie, additional, Higgs, Richard E., additional, Nirula, Ajay, additional, Cohen, Myron S., additional, and Marovich, Mary, additional

Published
2022
Full Text
View/download PDF

8. Additional file 1 of Relationship between gene expression patterns from nasopharyngeal swabs and serum biomarkers in patients hospitalized with COVID-19, following treatment with the neutralizing monoclonal antibody bamlanivimab

Author

Sims, Jonathan T., Poorbaugh, Josh, Chang, Ching-Yun, Holzer, Timothy R., Zhang, Lin, Engle, Sarah M., Beasley, Stephanie, Doman, Thompson N., Naughton, Lynn, Higgs, Richard E., Kallewaard, Nicole, and Benschop, Robert J.

Abstract

Additional file 1. Supplementary figures and methods.

Published
2022
Full Text
View/download PDF

9. The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination

Author

Crisp, Melissa, Kallewaard, Nicole L., Beasley, Stephanie, Daniels, Montanea, Freitas, Joshua J., Benschop, Robert J., Vaillancourt, Peter, Cohen, Myron S., Higgs, Richard E., Marovich, Mary, Haustrup, Natalie, Nirula, Ajay, Zhang, Lin, Trinh, Thi Ngoc Vy, Poorbaugh, Josh, and Tuttle, Jay L.

Abstract

As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout progresses, the availability and demand for monoclonal antibodies for the prevention and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are also accelerating. This longitudinal serological study evaluated the magnitude and potency of the endogenous antibody response to COVID-19 vaccination in participants who first received a COVID-19 monoclonal antibody in a prevention study. Over the course of six months, serum samples were collected from a population of nursing home residents and staff enrolled in a clinical trial who were randomized to either bamlanivimab treatment or placebo. In an unplanned component of this trial, a subset of these participants was subsequently fully vaccinated with two doses of either SpikeVax (Moderna) or Comirnaty (BioNTech/Pfizer) COVID-19 mRNA vaccines. This post-hoc analysis assessed the immune response to vaccination for 135 participants without prior SARS-CoV-2 infection. Antibody titers and potency were assessed using three assays against SARS-CoV-2 proteins that bamlanivimab does not efficiently bind to, thereby reflecting the endogenous antibody response. All bamlanivimab and placebo recipients mounted a robust immune response to full COVID-19 vaccination, irrespective of age, risk-category, and vaccine type with any observed differences of uncertain clinical importance. These findings are pertinent for informing public health policy with results that suggest that the benefit of receiving COVID-19 vaccination at the earliest opportunity outweighs the minimal effect on the endogenous immune response due to prior prophylactic COVID-19 monoclonal antibody infusion.

Published
2022
Full Text
View/download PDF

10. Longitudinal Assessment of Systemic Steroid Therapy on Hyperinflammatory Endothelial Biomarker Profiles and Serology Responses of COVID-19 Patients

Author

Sims, Jonathan Thomas, primary, Chang, Ching-Yun, additional, Poorbaugh, Josh, additional, Daniels, Montanea, additional, Beasley, Stephanie, additional, Zhang, Lin, additional, Rodgers, George, additional, Lena, Fabio, additional, Lacerenza, Leonardo, additional, Sposato, Bruno, additional, Dupont, Annabelle, additional, Susen, Sophie, additional, Casalini, Giacomo, additional, Corbellino, Mario, additional, Stebbing, Justin, additional, and Krishnan, Venkatesh, additional

Published
2022
Full Text
View/download PDF

11. The effect of anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, on endogenous immune response to COVID-19 vaccination

Author

Benschop, Robert J., primary, Tuttle, Jay L., additional, Zhang, Lin, additional, Poorbaugh, Josh, additional, Kallewaard, Nicole L., additional, Vaillancourt, Peter, additional, Crisp, Melissa, additional, Vy Trinh, Thi Ngoc, additional, Freitas, Joshua J., additional, Beasley, Stephanie, additional, Daniels, Montanea, additional, Haustrup, Natalie, additional, Higgs, Richard E., additional, Nirula, Ajay, additional, Cohen, Myron S., additional, and Marovich, Mary, additional

Published
2021
Full Text
View/download PDF

12. Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together

Author

Zhang, Lin, primary, Poorbaugh, Josh, additional, Dougan, Michael, additional, Chen, Peter, additional, Gottlieb, Robert L., additional, Huhn, Gregory, additional, Beasley, Stephanie, additional, Daniels, Montanea, additional, Ngoc Vy Trinh, Thi, additional, Crisp, Melissa, additional, Freitas, Joshua Joaquin, additional, Vaillancourt, Peter, additional, Patel, Dipak R., additional, Nirula, Ajay, additional, Kallewaard, Nicole L., additional, Higgs, Richard E., additional, and Benschop, Robert J., additional

Published
2021
Full Text
View/download PDF

13. 146. Intact Sense of Taste and Smell During COVID-19 Infection Is Associated with Absence of of SARS-CoV-2 Spike Protein Antibody Responses within 3 Months of Symptomatic Illness

Author

Wilson, James M, primary, Gillani, Sheena, additional, Bencshop, Robert, additional, Poorbaugh, Josh, additional, Nirula, Ajay, additional, Zhang, Lin, additional, Keckler, Kody, additional, Weber, Kathleen, additional, Morack, Ralph, additional, Beasley, Stephanie, additional, Brothers, Jennifer, additional, and Huhn, Gregory, additional

Published
2021
Full Text
View/download PDF

14. First‐in‐Human Study of Bamlanivimab in a Randomized Trial of Hospitalized Patients With COVID‐19

Author

Chen, Peter, primary, Datta, Gourab, additional, Grace Li, Ying, additional, Chien, Jenny, additional, Price, Karen, additional, Chigutsa, Emmanuel, additional, Brown‐Augsburger, Patricia, additional, Poorbaugh, Josh, additional, Fill, Jeffrey, additional, Benschop, Robert J., additional, Rouphael, Nadine, additional, Kay, Ariel, additional, Mulligan, Mark J., additional, Saxena, Amit, additional, Fischer, William A., additional, Dougan, Michael, additional, Klekotka, Paul, additional, Nirula, Ajay, additional, and Benson, Charles, additional

Published
2021
Full Text
View/download PDF

17. The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination

Author

Benschop, Robert J., Tuttle, Jay L., Zhang, Lin, Poorbaugh, Josh, Kallewaard, Nicole L., Vaillancourt, Peter, Crisp, Melissa, Trinh, Thi Ngoc Vy, Freitas, Joshua J., Beasley, Stephanie, Daniels, Montanea, Haustrup, Natalie, Higgs, Richard E., Nirula, Ajay, Cohen, Myron S., and Marovich, Mary

Abstract

As the coronavirus disease 2019 (COVID-19) pandemic evolves and vaccine rollout progresses, the availability and demand for monoclonal antibodies for the prevention and treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are also accelerating. This longitudinal serological study evaluated the magnitude and potency of the endogenous antibody response to COVID-19 vaccination in participants who first received a COVID-19 monoclonal antibody in a prevention study. Over the course of six months, serum samples were collected from a population of nursing home residents and staff enrolled in a clinical trial who were randomized to either bamlanivimab treatment or placebo. In an unplanned component of this trial, a subset of these participants was subsequently fully vaccinated with two doses of either SpikeVax (Moderna) or Comirnaty (BioNTech/Pfizer) COVID-19 mRNA vaccines. This post-hoc analysis assessed the immune response to vaccination for 135 participants without prior SARS-CoV-2 infection. Antibody titers and potency were assessed using three assays against SARS-CoV-2 proteins that bamlanivimab does not efficiently bind to, thereby reflecting the endogenous antibody response. All bamlanivimab and placebo recipients mounted a robust immune response to full COVID-19 vaccination, irrespective of age, risk-category, and vaccine type with any observed differences of uncertain clinical importance. These findings are pertinent for informing public health policy with results that suggest that the benefit of receiving COVID-19 vaccination at the earliest opportunity outweighs the minimal effect on the endogenous immune response due to prior prophylactic COVID-19 monoclonal antibody infusion.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results